Skip to navigation menu Skip to content
Informational Alert

Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Illustration of a calendarIllustration of a document pageIllustration of a heart over a handIllustration of an envelopeIllustration of the letter i inside a circleIllustration of a map markerIllustration of a caduceusIllustration of a user with a plus signIllustration of a telephoneIllustration of a question mark inside a circleIllustration of a video cameraDocument with a PDF label
Current Research Studies

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study (TSC-STEPS)

TSC-STEPS

What is the goal of the study?

This trial will use a phase IIb, randomized, double-blind, placebo-controlled, multicenter clinical trial design to evaluate the safety and efficacy of early sirolimus treatment to prevent epilepsy in TSC infants 0-12 months of age (N=64). Subjects will be between the ages of 0-6 months at the time of treatment initiation and meet clinical and/or genetic diagnostic criteria for TSC and have no prior history of seizures (clinical or electrographic) at the time of enrollment. Treatment will be continued until subjects reach 12 months of age.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: